|Bid||0.00 x 1800|
|Ask||0.00 x 800|
|Day's Range||67.67 - 72.93|
|52 Week Range||54.26 - 134.00|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||128.00|
SAN DIEGO, Jan. 02, 2019 -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet.
The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors endured a torrid quarter, which certainly propelled them to adjust their equity holdings so as to maintain the desired risk profile. As […]
NEW YORK, Nov. 26, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Reported positive top-line data from an interim analysis of its ongoing Phase 2a proof-of-concept clinical trial of etokimab in severe eosinophilic asthmaInitiated Phase 2.
The biopharma announced positive top-line data from a phase 2a trial involving its lead drug candidate as a treatment for asthma.
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of 19.72% and -100.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Shares of microcap stocks have surged to record highs, far outpacing the broader market, and that may be a bearish signal. According to Maley, since 2007 there have been six previous instances when the iShares Microcap ETF ( IWC) outperformed the S&P 500 Index (SPX) over the course of several months. The iShares Microcap ETF had an all-time record high close on June 6, up 12% year-to-date.